Anodyne Nanotech Raises $12.6M Series A to Move a Needle-Free Once-Weekly GLP-1 Patch Into Phase 1
Anodyne Nanotech closed a $12.6 million Series A, led by Velocity Partners, to advance ANN-101, a once-weekly GLP-1 skin patch, into first-in-human trials. The Boston company's HeroPatch solid-state microneedle platform delivers multi-milligram doses of peptides without injections or cold storage, aiming to reach the drug exposures obesity treatment requires. The round adds to a wave of investment in alternatives to weekly GLP-1 injections.